AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine
Status:
Terminated
Trial end date:
2016-05-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well AZD2171 works in treating patients with
neurofibromatosis type 1 and plexiform neurofibroma and/or neurofibroma near the spine.
AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth and by blocking blood flow to the tumor.